We found GANT61, a GLI1/GLI2 specific antagonist, could synergize with ICG001 to sensitize CAPN2-high HCC cells towards Lenvatinib to the extent as CAPN2 knockdown did (Fig. 4g and h). Here, CAPN2 is linked to hepatocellular carcinoma.